Novavax Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include: A co-exclusive license to co-commercialize Novavax’s current...
A personalized mRNA-based cancer vaccine for glioblastoma with an “onion-like” delivery mechanism can prolong survival both in dogs and humans, the results of a small study have suggested. In an article published May 1 in Cell, researchers from the University of...
SAN DIEGO, CA—“The future of cancer vaccines is now.” That’s the first thing that Geneos Therapeutics’ CEO and president, Niranjan Sardesai, PhD, said in an interview with GEN Edge at AACR 2024. “We’re at a point in time where there is no longer any doubt that...
RNA-based immunizing agents have enriched the repertoire of technologies used for vaccine development. An analysis of the active clinical trials in early Phase I and Phase I during the year of 2023 illustrates this point. A total of 161 active vaccine trials were...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced that it has received a Notice of Allowance from the Japanese Patent Office for a Patent (“Patent”) for inducing an antibody immune...
